BEAM THERAPEUTICS INC. Item 2.02 Results of Operations and Financial Condition.
On
The information in this Item 2.02 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 7.01 Regulation FD Disclosure.
Beam will be conducting meetings with participants attending the 40th Annual
The information in this Item 7.01 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filling.
Item 8.01 Other Events. Press Release
On
Collaboration with Pfizer Inc.
On
Cautionary Note Regarding Forward-Looking Statements
Statements in this Current Report on Form 8-K and in the exhibits incorporated
herein by reference about future expectations, plans and prospects, as well as
any other statements regarding matters that are not historical facts, may
constitute "forward-looking statements" within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements include, but are not
limited to, statements concerning activities under Beam's research collaboration
with Pfizer, future payments Beam may receive under such collaboration, Beam's
participation in the
--------------------------------------------------------------------------------
cell disease; the advancement of Beam's pipeline, including the submission of
INDs for BEAM-102 and BEAM-201, and the advancement of BEAM-102, BEAM-201,
BEAM-301, additional CAR-T and liver programs, and Stargardt disease program in
multiple preclinical studies; the potential activities under license and
collaboration agreements and the formation of new collaborations; and the
therapeutic applications and potential of Beam's technology, including Beam's
potential to develop life-long, curative, precision genetic medicines for
patients through base editing, including potential safety advantages. The words
"anticipate," "believe," "continue," "could," "estimate," "expect," "intend,"
"may," "plan," "potential," "predict," "project," "should," "target," "will,"
"would" and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these
identifying words. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important factors,
including: Beam's ability to develop, obtain regulatory approval for, and
commercialize its product candidates, which may take longer or cost more than
planned; Beam's ability to raise additional funding, which may not be available;
Beam's ability to obtain, maintain and enforce patent and other intellectual
property protection for its product candidates; the potential impact of the
COVID-19 pandemic; that preclinical testing of Beam's product candidates and
preliminary or interim data from preclinical studies and clinical trials may not
be predictive of the results or success of ongoing or later clinical trials;
that initiation and enrollment of Beam's clinical trials may take longer than
expected; that Beam's product candidates may experience manufacturing or supply
interruptions or failures; risks related to competitive products; whether the
research collaboration with Pfizer will result in programs that are licensed
from Beam; whether any product candidates that arise from these programs or are
otherwise developed by Beam will advance into clinical trials or through the
clinical trial process on a timely basis or at all; whether the results of
clinical trials of product candidates will warrant submissions for regulatory
approval or regulatory approval; whether any products that receive regulatory
approval will be successfully distributed and marketed; whether Beam's actual
audited results will be consistent with its estimated cash, cash equivalents and
marketable securities as of
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Exhibit No. Description 99.1Beam Therapeutics Inc. Presentation at the 40th Annual J.P. Morgan Healthcare Conference 99.2 Press Release Issued byBeam Therapeutics Inc. onJanuary 9, 2022 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source
